MARKET COMPOSITE
Market TodayThemes and Stocks SummaryThematic Stock SearchDaily Refresh Schedule
INO - Inovio Pharmaceuticals Inc
$10.58
0.86(8.85%)8:59:58 PM 1/26/2021
Inovio Pharmaceuticals is an American biotechnology company focused on the discovery, development, and commercialization of synthetic DNA products for treating cancers and infectious diseases. In April 2020, Inovio was among some 100 companies, academic centers, or research organizations developing a vaccine candidate for treating people infected with COVID-19, with more than 170 total vaccine candidates in development . The Inovio technology is based on inserting engineered DNA into cells where it becomes incorporated into proteins involved in the immune response to cancers and viruses by producing T cells and antibodies that aid recovery from infection. The technology can be "targeted" to specific types of cancer and immune diseases, such as those produced by a virus.
Stock Chart

Summary:

  • Price Zscore is at a recent 2 week high. A recent high ZScore means price movement is accelerating at a record speed.
  • Volatility is at a recent 2 week high. A high volatility of stock movement indicates uncertainty.
  • MACD is crossing MACD signal line at 0.2. MACD crossing signal line is bullish signal.

Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from 

Finra

Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.

Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.

Related Topics
Peers

Stock news

    01/25/2021INO
    INOVIO Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

    INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, including COVID-19, cancer and HPV-associated diseases, today announced the closing of its previously announced underwritten public offering of 20,355,000 shares of its common stock, which includes 2,655,000 shares sold pursuant to the underwriters' exercise in full of their option to purchase additional shares, a...

    01/22/2021INO
    Should Inovio Be On Your Buy List As It Tackles A Coronavirus Vaccine?

    Inovio has thrown its hat into the coronavirus vaccine ring with big biopharma names like Moderna, Johnson & Johnson and Pfizer. But INO stock is volatile on its vaccine news.

    01/22/2021INO
    What Is The Ownership Structure Like For Inovio Pharmaceuticals, Inc. (NASDAQ:INO)?

    If you want to know who really controls Inovio Pharmaceuticals, Inc. ( NASDAQ:INO ), then you'll have to look at the...

    01/21/2021INO
    Inovio Falls After $150 Million Share Offering Unveiled

    Inovio said in December that its covid vaccine candidate was in Phase 2 clinical trials. It's now raising new capital to help finance its clinical pipeline.

    01/21/2021INO
    Inovio's stock falls after it announces public offering

    Shares of Inovio Pharmaceuticals Inc. were down 5.1% in premarket trading on Thursday, the day after the company announced a public offering of 17,700,000 shares at $8.50 per share. The stock closed Wednesday at $9.72. Inovio said it will use the proceeds to support its clinical pipeline, which includes ongoing development of its COVID-19 vaccine candidate, which is currently being tested in a mid-stage clinical trial, and general corporate expenses. The offering is expected to close Jan. 25. In...

    01/21/2021INO
    The Daily Biotech Pulse: Addex Jumps On Positive Data For Out-Licensed Drug, COVID-19 Vaccine Developer Inovio Announces $150M Follow-On Offering, Boston Scientific Goes Shopping

    Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Jan. 20) * 10X Genomics Inc (NASDAQ: TXG) * ABIOMED, Inc. (NASDAQ: ABMD) * Aclaris Therapeutics Inc (NASDAQ: ACRS) * Adamis Pharmaceuticals Corp(NASDAQ: ADMP) (announced IND submission of Tempol for COVID-19 treatment) * Akari Therapeutics PLC (NASDAQ: AKTX) * Aligos Therapeutics Inc (NASDAQ: ALGS) * Alimera Sciences Inc (NASDAQ: ALIM) * Atea Pharmaceut...

    01/21/2021INO
    Inovio Sinks 7% After Pricing Of $150.5M Share Offering; Street Says Hold

    Shares of Inovio Pharmaceuticals dropped about 7% in Thursday’s pre-market trading after the biotech company priced its $150.5 million share offering. Inovio (INO) is offering to sell 17,700,000 shares of its common stock at a price of $8.50 per piece, reflecting a 14% discount to the closing price on Jan. 20. Furthermore, Inovio has granted the underwriters of the offering a 30-day option to buy up to an additional 2,655,000 shares of common stock. The share sale is expected to close by January...

    01/21/2021INO
    INOVIO Announces Pricing of Public Offering of Common Stock

    INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, including COVID-19, cancer and HPV-associated diseases, today announced the pricing of an underwritten public offering of 17,700,000 shares of its common stock at a public offering price of $8.50 per share. In addition, INOVIO has granted the underwriters a 30-day option to purchase up to an additional 2,655,000 s...

    01/20/2021INO
    INOVIO Announces Proposed Public Offering of Common Stock

    INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, including COVID-19, cancer and HPV-associated diseases, today announced that it has commenced an underwritten public offering of $150 million of shares of its common stock. All of the shares are being offered by INOVIO. In addition, INOVIO intends to grant the underwriters a 30-day option to purchase up to an addi...